# **SAFETY DATA SHEETS**

# This SDS packet was issued with item:

078930579

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078342777

# SAFETY DATA SHEET



### 1. Identification

Product identifier Digoxin Oral Solution USP

Other means of identification None.

Recommended use Treatment of mild to moderate heart failure

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

**Company name** Boehringer Ingelheim Roxane Inc.

Address 1809 Wilson Road

Columbus, Ohio 43228

**Telephone** (614) 276-4000 **Emergency phone number** (614) 276-4000

## 2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Carcinogenicity Category 2

OSHA defined hazards Not classified.

Label elements



Signal word Warning

Hazard statement This is a pharmaceutical product designed to be prescribed by a licensed health care

professional. Should any person while using this product observe any adverse health effects, they

should seek medical treatment.

Suspected of causing cancer.

**Precautionary statement** 

Prevention Observe good industrial hygiene practices. Do not handle until all safety precautions have been

read and understood. Wear protective gloves/protective clothing/eye protection/face protection.

**Response** Wash hands after handling. If exposed or concerned: Get medical advice/attention.

Storage Store away from incompatible materials. Store at 20° to 25°C (68° to 77°F); excursions permitted

to 15° to 30°C (59° to 86°F). Protect from light. Store locked up.

**Disposal** Incineration of waste at an approved USEPA incinerator is recommended.

Hazard(s) not otherwise

classified (HNOC)

None known.

## 3. Composition/information on ingredients

Revision date: -

#### **Substances**

923194

Chemical name	Common name and synonyms	CAS number	%	
Digoxin		20830-75-5	0.05 mg/mL	

Composition comments Refer to Physician's Desk Reference for common components present at <1%

4. First-aid measures

Version #: 01

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

**Skin contact** Wash off with soap and water. Get medical attention if irritation develops and persists.

**Eye contact** Rinse with water. Get medical attention if irritation develops and persists.

Issue date: 05-December-2014

Digoxin Oral Solution USP SDS US

1/6

**Ingestion** Rinse mouth. Get medical attention if symptoms occur. If ingestion of a large amount does occur,

of the intestines. Symptoms include nausea, vomiting, and diarrhea.

call a poison control center immediately.

Most important

symptoms/effects, acute and

delayed

Product has been associated with abdominal pain, intestinal ischemia, and hemorrhagic necrosis

Indication of immediate medical attention and special treatment needed

Patients who have intentionally or accidently ingested massive doses should receive activated charcoal orally or by nasogastric tube.

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Use water spray to cool unopened containers.

Specific methods
General fire hazards

Use standard firefighting procedures and consider the hazards of other involved materials.

No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Wear appropriate personal protective equipment (See Section 8)

Methods and materials for containment and cleaning up Environmental precautions

Wipe up with absorbent material. Following product recovery, flush area with water. Incineration of waste at an approved USEPA incinerator is recommended.

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling.

Conditions for safe storage, including any incompatibilities

Store away from incompatible materials (see Section 10 of the SDS). Protect from light. Store at

25°C (77°F); excursions permitted to 15 - 30 °C (59 - 86 °F).

8. Exposure controls/personal protection

Occupational exposure limits

No exposure limits noted for ingredient(s).

**Biological limit values** 

No biological exposure limits noted for the ingredient(s).

Appropriate engineering

controls

Ventilation should be matched to conditions.

Individual protection measures, such as personal protective equipment

Eye/face protection

None required for consumer use. In laboratory, medical or industrial settings, safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting. Contact a health and safety professional for specific information.

Skin protection

**Hand protection** 

For consumer use, no unusual precautions are necessary.

Other

None required for consumer use. In laboratory, medical or industrial settings, gloves and lab coats are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary. Contact a health and safety professional for specific information.

Digoxin Oral Solution USP SDS US

923194 Version #: 01 Revision date: - Issue date: 05-December-2014

Respiratory protection None required for consumer use. Respirators may be required for certain laboratory and

manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a health and safety professional or manufacturer for specific information.

Wear appropriate thermal protective clothing, when necessary. Thermal hazards

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

## 9. Physical and chemical properties

Clear, colorless solution. **Appearance** 

Physical state Liquid. **Form** Liquid.

Clear colorless. Color Odor Not available. Odor threshold Not available. pН Not available. Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point **Evaporation rate** Not available. Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Explosive limit - lower (%) Not available. Explosive limit - upper (%) Not available.

Not available. Vapor pressure Vapor density Not available. Not available. Relative density Relative density temperature estimated

Solubility(ies)

Solubility (water) Insoluble Partition coefficient Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature** Not available. **Decomposition temperature** Not available. **Viscosity** 

# 10. Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport. Reactivity

**Chemical stability** Material is stable under normal conditions.

Possibility of hazardous

Version #: 01

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Exposure to light.

Strong oxidizing agents. Incompatible materials

Revision date: -

Digoxin Oral Solution USP 923194 3/6

Issue date: 05-December-2014

SDS US

No hazardous decomposition products are known.

products

## 11. Toxicological information

Information on likely routes of exposure

InhalationNot expected to be hazardous in final pharmaceutical form.Skin contactNot expected to be hazardous in final pharmaceutical form.

Eye contact Not expected to be hazardous in final pharmaceutical form. Direct contact with eyes may cause

temporary irritation.

**Ingestion** Ingestion may cause irritation and malaise.

Symptoms related to the physical, chemical and toxicological characteristics

Product has been associated with abdominal pain, intestinal ischemia, and hemorrhagic necrosis

of the intestines. Symptoms also include nausea, vomiting, and diarrhea.

Information on toxicological effects

**Acute toxicity** May be harmful if swallowed in large quantities.

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Serious eye damage/eye Direct contact with eyes may cause temporary irritation.

irritation

Respiratory or skin sensitization

**Respiratory sensitization** Not a respiratory sensitizer.

Skin sensitization Rash and other skin reactions have been observed.

Germ cell mutagenicity No mutagenicity studies have been conducted

Carcinogenicity Suspected of causing cancer. In finished product form, risk of occupational exposure is expected

to be limited.

IARC Monographs. Overall Evaluation of Carcinogenicity

Digoxin (CAS 20830-75-5) 2B Possibly carcinogenic to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicity Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women.

There should be no pharmacologic effect upon the infant, nevertheless, caution should be

exercised when administered to a nursing woman.

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazard Not classified.

Further information See package insert.

12. Ecological information

**Ecotoxicity** The product is not classified as environmentally hazardous. **Persistence and degradability** No data is available on the degradability of this product.

Bioaccumulative potential No data available.

Partition coefficient n-octanol / water (log Kow)

Digoxin (CAS 20830-75-5) 1.26

Mobility in soil No data available.

Revision date: -

Other adverse effects None.

13. Disposal considerations

**Disposal instructions**Collect and reclaim or dispose in sealed containers at licensed waste disposal site.

Issue date: 05-December-2014

**Local disposal regulations** Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

Version #: 01

products

923194

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions)

Digoxin Oral Solution USP SDS US

#### Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

## 14. Transport information

DOT

Not regulated as dangerous goods.

**IATA** 

Not regulated as dangerous goods.

**IMDG** 

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and

Not applicable.

the IBC Code

## 15. Regulatory information

**US** federal regulations

This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use.

OSHA GHS: GHS symbols in consumer packaged form are not required per OSHA 29 CFR 1910.1200(b)(5) and OSHA 29 CFR 1910.1200(b)(5)(iii).

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

**CERCLA Hazardous Substance List (40 CFR 302.4)** 

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

No

Hazard categories Immediate Hazard - No

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Chemical name	CAS number	Reportable quantity	Threshold planning quantity	Threshold planning quantity, lower value	Threshold planning quantity, upper value	
Digoxin	20830-75-5	10		10 lbs	10000 lbs	

SARA 311/312 Hazardous

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations Drug Enforcement Administration (DEA): Digoxin is not a controlled substance.

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act (SDWA)

Not regulated.

(ODIIA)

Not listed.

**US** state regulations

**US. Massachusetts RTK - Substance List** 

Digoxin (CAS 20830-75-5)

**US. New Jersey Worker and Community Right-to-Know Act** 

Digoxin (CAS 20830-75-5)

US. Pennsylvania Worker and Community Right-to-Know Law

Digoxin (CAS 20830-75-5)

Digoxin Oral Solution USP SDS US

#### **US. Rhode Island RTK**

Digoxin (CAS 20830-75-5)

### **US. California Proposition 65**

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

#### International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	Yes
Canada	Domestic Substances List (DSL)	Yes
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	Yes
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	Yes

<sup>\*</sup>A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

# 16. Other information, including date of preparation or last revision

**Issue date** 05-December-2014

Revision date - 01

References 1) Digoxin Oral Solution USP, Package Insert, Roxane Laboratories, Inc., Columbus, Ohio

2) PDR - Physicians Desk Reference.

3) Ariel Webinsight. Regulatory and ChemExpert Database.

#### **Disclaimer**

Boehringer Ingelheim Roxane Inc. cannot anticipate all conditions under which this information and its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently available.

Digoxin Oral Solution USP SDS US

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).